CSL in development of blood-derived Covid-19 treatment
Biotechnology giant CSL has begun development of a blood-derived treatment for Covid-19, known as COVID-19 Immunoglobulin. The Melbourne company believes the product could be used to treat people seriously ill with the complications caused by the virus, particularly those whose illness is progressing towards the need for ventilation. The treatment will be derived from blood…